<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518699</url>
  </required_header>
  <id_info>
    <org_study_id>Ha02-005</org_study_id>
    <nct_id>NCT01518699</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Effect of Ha44 Gel on the ECG in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in&#xD;
      Healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a randomized, double-blind, placebo- and active-controlled, crossover study&#xD;
      that evaluated the potential of Abametapir to prolong cardiac repolarization in healthy adult&#xD;
      subjects (total of 57 subjects).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-dummy technique was used to mask the treatments. The test product is a gel and the positive control is a tablet. The active test product was administered with placebo positive control, while the active positive control was administered with placebo test product. The placebo group received both placebos.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF</measure>
    <time_frame>36 hours</time_frame>
    <description>The primary endpoint is the difference between the active (HA44) and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Ha44 0.74% Gel) - ΔQTcF (placebo)] = ΔΔQTcF. This was compared with the difference between Moxifloxacin and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Moxifloxacin) - ΔQTcF (placebo)] = ΔΔQTcF</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Pediculosis</condition>
  <arm_group>
    <arm_group_label>HA44 Abametapir Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug plus positive-control placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus positive-control placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44</intervention_name>
    <description>Abametapir Lotion 0.74%</description>
    <arm_group_label>HA44 Abametapir Lotion</arm_group_label>
    <other_name>Abametapir Lotion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44 Placebo</intervention_name>
    <description>Ha44 Vehicle Gel without Abametapir</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Abametapir Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Placebo</intervention_name>
    <description>Moxifloxacin Placebo</description>
    <arm_group_label>HA44 Abametapir Lotion</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 400mg</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Moxifloxacin Active</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy male or female subject, 18 to 50 years of age, inclusive, at least 45 kg and&#xD;
             has a body mass index (BMI) of 18 to 33 kg/m2,&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant and not lactating or&#xD;
             prepared to practice highly effective birth control methods&#xD;
&#xD;
          -  The subject has normal 12-lead ECG results or, if abnormal, the abnormality is not&#xD;
             clinically significant (as determined by the investigator).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has evidence of cardiac conduction abnormalities&#xD;
&#xD;
          -  history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or&#xD;
             torsade de pointes, structural heart disease, or family history of Long QT syndrome&#xD;
             (suggested by sudden death of a close relative due to cardiac causes at a young age&#xD;
&#xD;
          -  potassium, calcium, or magnesium levels that are below the clinical laboratory's lower&#xD;
             limit of normal&#xD;
&#xD;
          -  laboratory test results at Screening are &gt;2 x the upper limit of normal (ULN) for&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST), &gt;1.5 x ULN for&#xD;
             bilirubin, or &gt;1.5 x ULN for creatinine&#xD;
&#xD;
          -  history or evidence of any clinically significant (as determined by the investigator)&#xD;
             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,&#xD;
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major&#xD;
             disease or malignancy (excluding non-melanoma skin cancer)&#xD;
&#xD;
          -  febrile illness or symptomatic viral, bacterial (including upper respiratory&#xD;
             infection), or fungal (non-cutaneous) infection within 1 week before clinic admission&#xD;
&#xD;
          -  supine mean systolic blood pressure &lt;90 or &gt;140 mmHg and a mean diastolic blood&#xD;
             pressure &lt;50 or &gt;90 mmHg&#xD;
&#xD;
          -  positive for HIV or hepatitis C antibody or hepatitis B antigen (HBsAg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Dietz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <results_first_submitted>May 16, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty seven (57) subjects were enrolled into the study. Of them 53 completed all 3 periods of the study.</recruitment_details>
      <pre_assignment_details>The subjects were divided into 6 intervention arms with sequences ABC, ACB, BAC, BCA, CAB and CBA, where A is HA 44 (Abametapir) gel + Moxifloxacin placebo; B is HA 44 placebo + Moxifloxacin placebo and C is Moxifloxacin 400 mg tablet + HA 44 placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABC</title>
          <description>The subjects received sequence ABC in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
in period 3 they received Moxifloxacin 400 mg tablet + HA 44 placebo.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence ACB</title>
          <description>The subjects received sequence ACB in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 2 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 placebo + Moxifloxacin placebo.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence BAC</title>
          <description>The subjects received sequence BAC in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 3 they received Moxifloxacin 400 mg tablet + HA 44 placebo.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence BCA</title>
          <description>The subjects received sequence BCA in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 2 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 gel + Moxifloxacin placebo tablet.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence CAB</title>
          <description>The subjects received sequence CAB in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 placebo + Moxifloxacin placebo.</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence CBA</title>
          <description>The subjects received sequence CBA in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 gel + Moxifloxacin placebo tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Sequence ABC</title>
          <description>The subjects received sequence ABC in the three periods with a 4 day washout in between the periods. In each treatment period, subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
in period 3 they received Moxifloxacin 400 mg tablet + HA 44 placebo.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Sequence ACB</title>
          <description>The subjects received sequence ACB in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 2 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
in period 3 they received HA 44 placebo + Moxifloxacin placebo.</description>
        </group>
        <group group_id="B3">
          <title>Treatment Sequence BAC</title>
          <description>The subjects received sequence BAC in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 3 they received Moxifloxacin 400 mg tablet + HA 44 placebo.</description>
        </group>
        <group group_id="B4">
          <title>Treatment Sequence BCA</title>
          <description>The subjects received sequence BCA in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 2 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 gel + Moxifloxacin placebo tablet.</description>
        </group>
        <group group_id="B5">
          <title>Treatment Sequence CAB</title>
          <description>The subjects received sequence CAB in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 gel + Moxifloxacin placebo tablet, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 placebo + Moxifloxacin placebo.</description>
        </group>
        <group group_id="B6">
          <title>Treatment Sequence CBA</title>
          <description>The subjects received sequence CBA in the three periods with a 4 day washout in between two periods. In each treatment period subjects received a single dose of the treatment as follows:&#xD;
In period 1 they received Moxifloxacin 400 mg tablet + HA 44 placebo, followed by a 4 day washout period.&#xD;
In period 2 they received HA 44 placebo + Moxifloxacin placebo, followed by a 4 day washout period.&#xD;
In period 3 they received HA 44 gel + Moxifloxacin placebo tablet.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.47"/>
                    <measurement group_id="B2" value="28.0" spread="9.04"/>
                    <measurement group_id="B3" value="28.8" spread="7.21"/>
                    <measurement group_id="B4" value="28.2" spread="6.81"/>
                    <measurement group_id="B5" value="32.6" spread="9.70"/>
                    <measurement group_id="B6" value="33.8" spread="8.66"/>
                    <measurement group_id="B7" value="29.9" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF</title>
        <description>The primary endpoint is the difference between the active (HA44) and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Ha44 0.74% Gel) - ΔQTcF (placebo)] = ΔΔQTcF. This was compared with the difference between Moxifloxacin and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Moxifloxacin) - ΔQTcF (placebo)] = ΔΔQTcF</description>
        <time_frame>36 hours</time_frame>
        <population>All completed subjects</population>
        <group_list>
          <group group_id="O1">
            <title>HA 44 Gel + Moxifloxacin Placebo</title>
            <description>The maximal difference between baseline and post treatment value in QTcF</description>
          </group>
          <group group_id="O2">
            <title>HA 44 Placebo + Moxifloxacin Placebo</title>
            <description>The maximal difference between baseline and post treatment value in QTcF</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin 400 mg Tablet +HA 44 Placebo</title>
            <description>The maximum difference between baseline and post treatment values in QTcF</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF</title>
          <description>The primary endpoint is the difference between the active (HA44) and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Ha44 0.74% Gel) - ΔQTcF (placebo)] = ΔΔQTcF. This was compared with the difference between Moxifloxacin and placebo for time matched baseline adjusted mean QTcF = [ΔQTcF (Moxifloxacin) - ΔQTcF (placebo)] = ΔΔQTcF</description>
          <population>All completed subjects</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="10.27"/>
                    <measurement group_id="O2" value="-9.2" spread="10.10"/>
                    <measurement group_id="O3" value="6.1" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the time of signing informed consent until the last study assessment i.e. for 18 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HA44 Abametapir Lotion</title>
          <description>Study drug plus positive-control placebo.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo plus positive-control placebo.</description>
        </group>
        <group group_id="E3">
          <title>Moxifloxacin</title>
          <description>Placebo plus Moxifloxacin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Srinivas Sidgiddi</name_or_title>
      <organization>Dr. Reddy's Laboratories Inc.</organization>
      <phone>9084585362</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

